Pemetrexed as first-line therapy for non-squamous non-small cell lung cancer

Therapeutics and Clinical Risk Management

Volumn 5, Issue 1, 2009, Pages 781-787

  Ricciardi, Serena ^a   Tomao, Silverio ^b   De Marinis, Filippo ^a  

^a Thoracic Oncology Unit 1st   (Italy)

^b Sperimental Medicine Department   (Italy)

Author keywords

First line setting; Non small cell lung cancer; Non squamous carcinoma; Pemetrexed

Indexed keywords

CARBOPLATIN; CISPLATIN; CYANOCOBALAMIN; DEXAMETHASONE; FOLIC ACID; GEMCITABINE; NAVELBINE; OXALIPLATIN; PEMETREXED;

ALOPECIA; ANEMIA; BLOOD TOXICITY; CANCER GROWTH; CLINICAL TRIAL; DRUG INDICATION; GRANULOCYTOPENIA; HISTOPATHOLOGY; HUMAN; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; METASTASIS; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PLEURA MESOTHELIOMA; RASH; REVIEW; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 77949458607     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Grenlee RT, Murray T, Bolden S, et al. Cancer statistics 2000. CA Cancer J Clin. 2000;50:7-33.
2. Haus BM, Razavi H, Kuschner Wg. Occupational and environmental causes of bronchogenic carcinoma. Curr Opin Pulm Med. 2001;7:220-225.
3. Shepherd FA. Screnning, diagnosis amd staging of lung cancer. Curr Opin Oncol. 1993;5(2):310-322.
4. Wailing J. Chemotherapy for advanced non small cell lung cancer. Respir Med. 1994;88(9):649-657.
5. Jemal A, Murray T, Wand E, et al. Cancer statistics, 2005. Ca Cancer J Clin. 2005;55:10-30.
6. Bunn PA, Jr Kelly K. New chemotherapeutic agents prolong survival and improve quality of life in non small cell lung cancer:a review of the literature ad future directions. Clin Cancer Res. 1998;4:1087-1100.
7. Schiller JH, Harrington D, Belani C, et al. Comparison of four chemotherapy regimens for advanced non small cell lung cancer. N Engl J Med. 2002;346(2):92-98.
8. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non small cell lung cancer. N Engl J Med. 2006;355:2542-2550.
9. Scagliotti GV, De Marinis F, Rinaldi M, et al. Phase III randomized trial comparino three platinum-based doublets in advanced non small cell lung cancer. J Clin Oncol. 2002;20(21):4285-4291.
10. Shih C, Chen VJ, Gossetti LS, et al. LY231514, a pirrolo pyrimidine-based antifolate that inhibits multiple folate requiring enzymes. Cancer Res. 1997;57:1116-1123.
11. Tonkinson JL, Wagner MM, Paul DC, et al. Cell cycle modulation by the multi-targeted anti-folate, LY231514, increases the antiproliferative activity of gemcitabine. Proc Am Assoc Cancer Res. 1996;37:370.
12. Bunn P, Paoletti P, Niyikiza C, et al. Vitamin B12 and folate reduce toxicity of Alimta, a novel antifolate/antimetabolite. Proc Am Soc Clin Oncol. 2001;20:76a (abstract 300).
13. Pemetrexed, SPC [online]. Available at http://www.emea.europea.eu/ humandoes/alimta/H-564-PI-en.pdf.
14. Rusthoven JJ, Eisenhauer E, Butts C, et al. Multitargeted antifolate LY2311514 as first line chemotherapy for patients with advanced non small cell lung cancer: phase II study. J Clin Oncol. 1999;17:1194-1199.
15. Clarke SJ, Abratt R, Goedhals L, et al. Phase II trial of pemetrexed disodium in chemotherapy-naive patients with advanced non small cell lung cancer. Ann Oncol. 2002;13:737-741.
16. Gridelli C, Kaukel E, Gregorc V, et al. Single-agent pemetrexed or sequential pemetrexed/gemcitabine as front-line treatment of advanced NSCLC in elderly patients or patients ineligible for platinum-based chemtherapy: a multicenter , randomized, phase II trial. J Thorac Oncol. 2007;2:221-229.
17. Manegold C, Gatzemeier U, von Pawel J, et al. Front-line treatment of advanced non small cell lung cancer with MTA and cisplatin: a multicenter phase II trial. Ann Oncol. 2000;11:435-440.
18. Shepherd FA, Dancey J, Arnold A, et al. Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced NSCLC: a study of the National Cancer Institute of Canada clinical trials group. Cancer. 2001;92:595-600.
19. Scagliotti GV, Kortsik C, Dark GG, et al. Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced NSCLC: a multicenter , randomized, phase II trial. Clin Can Res. 2005;11:690-696.
20. Zinner RG, Fossella FV, Gladish GW, et al. Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced NSCLC. Cancer. 2005;104:2449-2456.
21. Monnerat C, Le Chevalier T, Kelly K, et al. Phase II study of pemetrexed-gemcitabine combination in patients with advanced stage NSCLC. Clin Cancer Res. 2004;10:5439-5446.
22. Adjei AA, Nair S, Reuter N, et al. Pemetrexed/Gemcitabine as frontline therapy for advanced NSCLC: a randomized, phase II trial of three schedules. Proc Am Soc Clin Oncol. 2004;23:630.
23. Treat J, Bonomi P, McCleod M, et al. Administration of pemetrexed immediately following gemcitabine as front-line therapy in advanced NSCLC: a phase II Trial. Lung Cancer. 2006;53:77-83.
24. Ye Z, Treat JA. Meta-analysis of pemetrexed plus gemcitabine in first-line, advanced NSCLC. J Clin Oncol. 2007;25(18S):18015a.
25. Adjei AA, Erlichman C, Sloan JA, et al. Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors. J Clin Oncol. 2000;18(8):1748-1757.
26. Monnerat C, Le Chevalier T, Kelly K, et al. Phase II study of pemetrexed-gemcitabine combination in patients with advanced-stage non-small cell lung cancer. Clin Cancer Res. 2004;10(16):5439-5446.
27. Ma CX, Nair S, Thomas S, et al. Randomized phase II trial of three schedules of pemetrexed and gemcitabine as front-line therapy for advanced non-small-cell lung cancer. J Clin Oncol. 2005;23(25):5929-5937.
28. Dy GK, Suri A, Reid JM, et al. A phase IB study of the pharmacokinetics of gemcitabine and pemetrexed, when administered in rapid sequence to patients with advanced solid tumors. Cancer Chemother Pharmacol. 2005;55(6):522-530.
29. West HL, Wakelee A, Perry MC, et al. Gemcitabine and pemetrexed administered in rapid sequence as front-line chemotherapy for advanced non-small-cell lung cancer: a phase II clinical trial. Ann Oncol. 2009 Jan 15. [Epub ahead of print].
30. Dudek A, Larson T, Mc Cleod M, et al. Phase 1/2 dose escalating study of twice-monthly pemetrexed and gemcitabine in patients with advanced cancer and non-small cell lungcancer. J Thorac Oncol. 2008;3(4):394-399.
31. Clarke SJ, Boyer MJ, Millward M, et al. A phase I/II study of pemetrexed and vinorelbine in patients with non small cell lung cancer. Lung Cancer. 2005;49:401-412.
32. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636-2644.
33. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non small cell lung cancer previously treatad with chemotherapy. J Clin Oncol. 2004;22:1589-1597.
34. Gronberg BH, Bremnes R, Aasebo U, et al. Pemetrexed plus carboplatin versus gemcitabine plus carboplatin in the treatment of stage IIIB/IV NSCLC. [oral presentation] Presented at the XX meeting, June 2007. J Clin Oncol. 2007;25 Suppl:7517a.
35. Scagliotti G, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage NSCLC. J Clin Oncol. 2008;26:3485-3486.
36. Sigmond J, Backus HH, Wouters D, et al. Induction of resistance to the multitargeted antifolate pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression. [abstract] Biochem Pharmacol. 2003;66:431-438.
37. Ceppi P, Volante M, Saviozzi S, et al. Squamous cell carcinoma of the lung compared with other istotypes shows higher messenger RNA and protein levels for tymidylate synthase. Cancer. 2006;107:1589-1596.
38. Peterson P, Park K, Fossella FV, et al. Is pemetrexed more effective in patients with non-squamous histology. A retrospective analysis of a phase III trial of pemetrexed vs docetaxel in previously treated patients with advanced NSCLC. [abstract] Eur J Cancer Suppl. 2007;5:363:6521.
39. Hirsch FR, Spreafico A, Novello S, et al. The prognostic and predictive role of histology in advanced NSCLC: a literature review. J Thorac Oncol. 2008;3:1468-14681.
40. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable NSCLC : update 2003. J Clin Oncol 2004;22:330-353.
41. Socinski MA.Cytotoxic chemotherapy in advanced NSCLC: a review of standard treatment paradigms. Clin Cancer Res. 2004;10:s4210s-s4214.
42. Ciuleanu TE, Brodowicz T, Belani CP, et al. Maintenance pemetrexed plus best supportive care (BSC) versus placebo plus BSC: a phase III study. [abstract] J Clin Oncol. 2008;26:426s. Abstract 8011.